The purpose of this study is to find out if radiation therapy along with the addition of the drugs, cisplatin and gemcitabine, works in treating locally advanced squamous cell carcinoma of the vulva and to find out what side effects or surgical complications are caused by treatment with this combination.
This is a Phase II study for women diagnosed with pelvic-only and or vaginal recurrence of endometrial cancer following complete hysterectomy and bilateral salpingo-oophorectomy at the time of initial diagnosis . Patients will be randomized to receive external pelvic radiation for approximately 5 weeks followed by brachytherapy OR external pelvic radiation for approximately 5 weeks plus weekly chemotherapy with cisplatin followed by brachytherapy. The study is designed as a screening study to estimate the benefit on progression-free survival of the addition of cisplatin to external pelvic irradiation, overall survival, side effects and evaluate factors at study entry and from original hysterectomy as potential prognostic factors.
This study is for women who have completed treatment (chemotherapy and other treatment) for state II, III, or IV ovarian, fallopian tube or primary peritoneal cancer (cancer having to do with the tissue that lines the inside of the abdomen and covers its organs) and are at risk for the cancer coming back.
This study is for female adult subjects with ovarian cancer. CA125 is a protein (compound made by the body) found in blood that is used to monitor treatments and disease progression in ovarian cancer patients. HE4 is also a protein that is used in the evaluation of ovarian cancer and disease monitoring. Both CA125 and HE4 are approved by the FDA to monitor the treatment of ovarian cancers. The purpose of this study is to investigate HE4 and CA125 expressions in different types of ovarian cancer and to evaluate the changes in HE4 and CA125 before and after treatment. A blood draw of approximately 5mL or 1 teaspoon will be taken from eligible subjects before surgery, before each course of chemotherapy and at the time of disease response assessment to evaluate HE4 and CA125 expression.
The purpose of this study is to see if a geriatric assessment tool in the form of a series of questions and lab work, given before surgery, will help predict complications from surgery in older women undergoing surgery for gynecologic cancers. A similar geriatric assessment tool is known to predict chemotherapy toxicity in older patients. If the geriatric assessment tool can tell us which older patients are at risk for surgical complications it could be useful to surgeons in treating elderly women with gynecologic cancers.
Multiple radiation treatments are frequently used to treat pain caused by cancer that has spread to the spine. Image-guided radiosurgery/stereotactic body radiation therapy (SBRT) is a treatment that uses highly focused x-rays to deliver a single high dose on a specific area of the body. Image-guided radiosurgery/SBRT uses special equipment to position the patient and guide the focused beams toward the area to be treated and away from normal tissue.
The purpose of this part of the study is to compare the effects, good and/or bad, of image-guided radiosurgery/SBRT to standard radiation therapy to find out which treatment provides the most rapid pain relief with the least side effects.
This study is for patients that have been diagnosed with platinum-sensitive ovarian cancer.The investigational drug in this study is Farletuzumab. The main purpose of this study is to find out if carboplatin plus paclitaxel or carboplatin plus Pegylated Liposomal Doxorubicin (PLD), chemotherapies (anticancer drugs) that are used to treat ovarian cancer, work better alone or when given with an farletuzumab.
The estimated total duration of this study will be approximately 46 months (1 month screening, 15 months treatment, and 30 months follow-up). The actual total duration will vary depending on subject response to drug and disease progression
The purpose of this study is to find out if providing patients with educational materials helps them to be better prepared for making a decision about participating in a research study to treat their cancer.
This phase II trial studies how well dasatinib works in treating patients with persistent ovarian, fallopian tube, endometrial, or peritoneal cancer. Dasatinib may shrink patients' tumors by blocking some of the enzymes needed for cell growth.